Alterity says FDA backs single Phase 3 path for ATH434 in MSA

Official meeting minutes confirmed the Phase 3 design previously disclosed on June 9, 2026, with trial activities still targeted to begin by year-end 2026.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.